GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Onconic Therapeutics 476060.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

11,610

-0.60%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Onconic Therapeutics

Its shares trade on KOSDAQ under the ticker 476060.KQ. It has been listed since 19 December 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩53.39bn and net income of ₩15.78bn. At that date it held total assets of ₩75.71bn and shareholders' equity of ₩72.04bn.

Onconic Therapeutics Inc is a KR-based company operating in industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-12-19. Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The firm mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
19 Dec 2024

Leadership

Pay as last reported

  • Mr. John KimChief Executive Officer
  • Jong Kil ShinChief Financial Officer
  • Hyun Ju ChaChief Scientific Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Onconic Therapeutics Inc develops Zastaprazan for acid-related diseases in South Korea.
  • Onconic Therapeutics Inc focuses on small molecule-based anticancer drugs like Nesuparib.
  • Onconic Therapeutics Inc operates in the South Korean market with a strong R&D focus.

Weaknesses

  • Onconic Therapeutics Inc has limited international market presence outside South Korea.
  • Onconic Therapeutics Inc's product portfolio is concentrated in specific disease areas.
  • Onconic Therapeutics Inc's IPO date is December 19, 2024, which is recent.

Opportunities

  • Onconic Therapeutics Inc can expand into global markets for acid-related disease treatments.
  • Onconic Therapeutics Inc may grow in the anticancer drug segment with Nesuparib.
  • Onconic Therapeutics Inc can leverage South Korea's healthcare advancements for new drug development.

Threats

  • Onconic Therapeutics Inc faces competition in the South Korean anticancer drug market.
  • Onconic Therapeutics Inc must navigate regulatory challenges for new drug approvals.
  • Onconic Therapeutics Inc's reliance on small molecule drugs could limit innovation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.